NYSE · Pharmaceutical Preparations
32 entities across 9 jurisdictions. Read directly from the company’s own 10-K EX-21 filed 2026-05-14 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Blacksmith Brands, Inc. | Delaware | |
| Briemar Nominees Pty Ltd. | Australia | |
| C.B. Fleet Investment Corporation | Delaware | |
| C.B. Fleet International LLC (formerly C.B. Fleet, International, Inc.) | Virginia | |
| C.B. Fleet International(s) Pte. Ltd | Singapore | |
| Care Acquisition Company Pty Limited | Australia | |
| Care Pharmaceuticals Pty Limited | Australia | |
| Cellegy Australia Pty | Australia | |
| Clear Eyes Pharma Limited | England and Wales | |
| DenTek Holdings, Inc. | Delaware | |
| DenTek Oral Care, Inc. | Tennessee | |
| DenTek Oral Care Limited | England and Wales | |
| Insight Pharmaceuticals Corporation | Delaware | |
| Insight Pharmaceuticals LLC | Delaware | |
| Medtech Holdings, Inc. | Delaware | |
| Medtech Online Inc. | Delaware | |
| Medtech Personal Products Corporation | Delaware | |
| Medtech Products Inc. | Delaware | |
| PBH Australia Holdings Company Pty Limited | Australia | |
| Pakaging Innovations Pty Ltd. | Australia | |
| Peaks HBC Company, Inc. | Virginia | |
| Pillar5Pharma Inc. | Canada | |
| Practical Health Products, Inc | Delaware | |
| Prestige Brands Holdings, Inc. | Virginia | |
| Prestige Brands, Inc. | Delaware | |
| Prestige Brands Gmbh | Germany | |
| Prestige Brands International, Inc. | Virginia | |
| Prestige Brands (UK) Limited | England and Wales | |
| Prestige Brands SPE Lender, LLC | Delaware | |
| Prestige Services Corp. | Delaware | |
| The Spic and Span Company | Delaware | |
| Wartner USA B.V. | Netherlands |
Two standard screens, computed from the XBRL in FY2026 against FY2025. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2021 | $943.4M | $164.7M | $213.4M | 58.0% | 50,605,000 |
| FY2022 | $1.1B | $205.4M | $250.3M | 57.1% | 50,842,000 |
| FY2023 | $1.1B | −$82.3M | $221.9M | 55.4% | 49,889,000 |
| FY2024 | $1.1B | $209.3M | $239.4M | 55.5% | 50,178,000 |
| FY2025 | $1.1B | $214.6M | $243.3M | 55.8% | 50,080,000 |
| FY2026 | $1.1B | $190.3M | $246.4M | 54.7% | 48,720,000 |
1 institutions tracked — 1 added, 0 reduced.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | Index | 1,571,742 | +111,707 | $74.3M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
What the company actually paid out and bought back, as reported — the record behind any yield figure.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Prestige Consumer Healthcare Inc. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
